Ranking · Winter 2024 · Healthcare · Therapeutics

Granza Bio

Building programmable therapeutics for the immune system

7.0%

odds of being acquired in the next two years

1.0× the average (6.8%)

#1876 of 4,339 active YC companies · top 44%

Team of 8 · San Francisco, CA, USA

Raises the odds

↑ 1.5–3 years since YC

↑ team of 6–10

↑ based in United States of America

↑ rewrote its description in the last six months

Lowers the odds

↓ industry: Healthcare

↓ “building” in its one-liner

↓ tag: Healthcare

From the model: how this company's profile compares with companies that were and weren't acquired since 2024. How it works.

Signals brief

ExitOdds reads Granza Bio's website and YC profile; Contextrie keeps the passages that bear on an acquisition, and every signal quotes its source.

3 free briefs left today

granzabio.com YC profile

Statistical estimate from public directory data as of 2026-10-07; it can't see revenue, funding or talks. Not investment advice. ExitOdds is independent and not affiliated with Y Combinator.

Built with open source on GitHub